Cell-Type-Specific Intracellular Protein Delivery with Inactivated Botulinum Neurotoxin

The ability to deliver proteins and peptides across the plasma membrane into the cytosol of living mammalian cells would be highly impactful for both basic science and medicine. Natural cell-penetrating protein toxins have shown promise as protein delivery platforms, but existing approaches are limited by immunogenicity, lack of cell-type-specificity, or their multi component nature. Here we explore inactivated botulinum neurotoxin (BoNT) as a protein delivery platform. Using split luciferase reconstitution in the cytosol as a readout for endosomal escape and cytosolic delivery, we showed that BoNT chimeras with nanobodies replacing their natural receptor binding domain can be selectively targeted to cells expressing nanobody-matched surface markers. We used chimeric BoNTs to deliver a range of cargo from 1.3 to 55 kDa in size, and demonstrated selective delivery of orthogonal cargoes to distinct cell populations within a mixed culture. These explorations suggest that BoNT may be a versatile platform for targeted protein and peptide delivery into mammalian cells.

Automated summary

The ability to deliver proteins and peptides across the plasma membrane into the cytosol of living mammalian cells has significant implications for basic science and medicine. In this study, we investigated the use of inactivated botulinum neurotoxin (BoNT) as a protein delivery platform, and found that nanobody-chimeric BoNTs can be selectively targeted to specific cells by replacing their natural receptor binding domain. These findings suggest that BoNT could be a versatile platform for targeted protein and peptide delivery into mammalian cells.